Incidence of Anti-Drug Antibody Development in Older Adults with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Inhibitors: A Large Multicenter Cohort Study
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izaf170 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Spencer Frost und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, United States. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Tumor Necrosis Factor-alpha, Tumor Necrosis Factor Inhibitors, Antibodies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
It has been theorized that age related immunosenescence reduces the risk of developing anti-drug antibodies (ADAs). This has significant implications regarding choice of therapy and need for routine drug monitoring in this group. We investigated the incidence of ADAs in older adults compared to younger adults with inflammatory bowel disease (IBD).
Methods
We conducted a multicenter retrospective cohort study including all older adults (ages ≥60 years) with IBD treated with a tumor necrosis factor inhibitors (TNFi); adults ages 18-59 years old were included in a 4:1 ratio. Kaplan-Meier and Cox regression methods compared longitudinal risk of ADA development between groups. Multivariable models evaluated the association of potential risk factors with ADA development.
Results
182 (19.7%) older adults and 738 (80.2%) younger adults were included in the study. The risk of ADAs was higher in older adults compared to younger adults (adjusted hazard ratio [aHR] 2.20; 95% confidence interval [CI] 1.44-3.36). Proactive therapeutic drug monitoring (TDM) was inversely associated with ADA development (aHR 0.36; 95% CI 0.25-0.52).
Conclusion
Older adults are more likely to develop ADAs against TNFi compared to younger adults. Proactive TDM may be considered in this population for early identification of ADAs and subtherapeutic trough levels, enabling timely dose escalation or treatment modification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, United States.
- Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States.
- Division of Digestive Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
- Division of Gastroenterology, University of California Irvine, Irvine, CA, United States.
- Department of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, MD, United States.
- Department of Medicine, Johns Hopkins University, Baltimore, MD, United States.
ORCID-Profile: Chetan Ambastha, Sunhee Park, Alyssa Parian, Kian Keyashian
Zitieren
APA
Frost, S., Ambastha, C., Patel, D., Roney, A., Greb, A., Rangel-Garcia, M., Sauk, J. S., Chang, C., Park, S., Parian, A., Suchan, A., Moughames, E., Krishna, M., Chowdhury, R., Sharma, S., Maas, L., Ho, A., Lazarev, M., Limketkai, B. N., …, & Keyashian, K. (2025). Incidence of Anti-Drug Antibody Development in Older Adults with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Inhibitors: A Large Multicenter Cohort Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf170
Vancouver
Frost S, Ambastha C, Patel D, Roney A, Greb A, Rangel-Garcia M, et al. Incidence of Anti-Drug Antibody Development in Older Adults with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Inhibitors: A Large Multicenter Cohort Study. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf170
BibTeX
@article{Frost2025,
author = {Frost, Spencer and Ambastha, Chetan and Patel, Devin and Roney, Andrew and Greb, Alexandra and Rangel-Garcia, Maricela and Sauk, Jenny S and Chang, Christopher and Park, Sunhee and Parian, Alyssa and Suchan, Andrew and Moughames, Eric and Krishna, Mahesh and Chowdhury, Reezwana and Sharma, Sowmya and Maas, Laura and Ho, Andrew and Lazarev, Mark and Limketkai, Berkeley N and Limsui, David and Keyashian, Kian},
title = {Incidence of Anti-Drug Antibody Development in Older Adults with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Inhibitors: A Large Multicenter Cohort Study},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izaf170}
}
EUVIMED